Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 tha...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

ButcherBillCutting Jul. 7 at 4:27 PM

$ATHE Big long fireside chat with detailed Q & A after that I was able to watch Took some notes & need to review I encourage current holders or buyers Considering to check it out when You have an hour of free time Dr. Stamler knows what he’s doing, With his past work & present day https://youtu.be/BMQu6cAc4is?si=sjRDPK5_aKIPmyZQ

0 · Reply

motherlandreturns Jul. 3 at 1:16 PM

$ATHE I guess we are still waiting for a buy out or partnership 🤑

1 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 1 at 9:21 PM

$SLS Copied from chat.. I believe $ATHE will be a multibagger (6x) I believe $CING will be a multibagger (8x) I believe SLS will be a multibagger. (20x) I believe $PYPD will be a multi-bagger (10x) I believe RILY will be a multibagger. (4x) I believe ANRO will be a multibagger (15x) Oust will double ( or more) before I sell it. I'm up 40% on Slpd since I mentioned it in the group. And Bar may have found something with poet. My trading account is spread equally across those ... even though I believe in SLS the most. Stick and move.... Stick and move....

2 · Reply

CARTE_BLANCHE_DEVEREAUX Jun. 27 at 6:15 PM

$SLS $HYPD Lol, Stocktwits not adjusting for split. Closed this position for a nice profit today though. Gains split between SELLAS, $POET and $ATHE (I'm back to 60k shares finally!!!!)

1 · Reply

GA09 Jun. 27 at 12:57 PM

$ATHE I have invested and traded several biotech stocks and I have to state that Dr Stamler is the best CEO I have seen so far. He has 3 FDA approvals behind him, passionate about treating Parkinson's related diseases, transparent, honest, pleasant, answers analysts questions in detail and completely transparent, extensive experience and working tirelessly to get the 434 approved and on the market ASAP so people who need this treatment and get it ASAP. This is why I am extremely confident they will find the right partner or will get acquired sooner rather than later (after releasing data in July) and will retain a seat and have a say on 434 and its approval and release and will continue to work on additional indications of 434 to treat Parkinson's related diseases. I would be a buyer on any pullbacks before we get data in July. I also liked the fact that he said he reviews each data scrupulously and is a perfectionist with reviewing data.

0 · Reply

glanvill Jun. 26 at 11:58 PM

$ATHE The presentation was excellent. The explanation that the difference between 50mg and 75mg results in the P2 is explained by baseline differences in the treatment group is compelling.

0 · Reply

jetwash Jun. 26 at 6:38 AM

$ATHE 45:20 mark - The company last ran profitability models in 2023 with the assumption 434 could improve Orthostatic symptoms. It was 1B peak sales in US alone. NOW, with latest data showing it also improves UMSARS score, it's time to double that .

2 · Reply

theaussiebloke Jun. 26 at 1:12 AM

$ATHE Yesterdays presentation is now available on Alteritys presentations site...enjoy

1 · Reply

VicTruth17 Jun. 26 at 12:18 AM

$ATHE here’s the 3 month chart with that $3.55 gap the MMs will try to fill… they have 2 weeks at most… then it’s off to the races again… We’ll hover around $3.50-$3.70 until July 1st…. Happy tradings and the company is still valued at $2-3b :)

1 · Reply

VicTruth17 Jun. 25 at 6:53 PM

$ATHE will post my thoughts soon but looking at the 3 month chart and trading patterns… there is a gap to be filled at $3.55… Looking to rebuy within the week… playing with fire but they are burning us any chance they get 😫

2 · Reply

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

May 12, 2025, 7:35 AM EDT - 2 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 2 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 5, 2025, 7:35 AM EDT - 2 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Apr 30, 2025, 7:35 AM EDT - 2 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 28, 2025, 7:35 AM EDT - 2 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 10, 2025, 7:35 AM EDT - 3 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Mar 27, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Feb 10, 2025, 7:25 AM EST - 5 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

Jan 30, 2025, 7:35 AM EST - 5 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 24, 2025, 7:35 AM EST - 5 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 9, 2025, 7:25 AM EST - 6 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Dec 4, 2024, 7:35 AM EST - 7 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 8 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 8 months ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 6, 2024, 7:35 AM EST - 8 months ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Oct 31, 2024, 7:35 AM EDT - 8 months ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 14, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 11, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 10 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 23, 2024, 7:35 AM EDT - 10 months ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Feb 20, 2024, 10:25 AM EST - 1 year ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 6, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Jan 29, 2024, 7:24 AM EST - 1 year ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Dec 21, 2023, 12:30 AM EST - 1 year ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 4, 2023, 4:35 PM EST - 1 year ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Nov 27, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Nov 16, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Nov 8, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Oct 30, 2023, 7:25 AM EDT - 1 year ago

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Aug 31, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Aug 23, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's

Aug 22, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders

Aug 15, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Jul 31, 2023, 7:52 AM EDT - 2 years ago

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Jul 26, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

ButcherBillCutting Jul. 7 at 4:27 PM

0 · Reply

motherlandreturns Jul. 3 at 1:16 PM

$ATHE I guess we are still waiting for a buy out or partnership 🤑

1 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 1 at 9:21 PM

2 · Reply

CARTE_BLANCHE_DEVEREAUX Jun. 27 at 6:15 PM

$SLS $HYPD Lol, Stocktwits not adjusting for split. Closed this position for a nice profit today though. Gains split between SELLAS, $POET and $ATHE (I'm back to 60k shares finally!!!!)

1 · Reply

GA09 Jun. 27 at 12:57 PM

0 · Reply

glanvill Jun. 26 at 11:58 PM

$ATHE The presentation was excellent. The explanation that the difference between 50mg and 75mg results in the P2 is explained by baseline differences in the treatment group is compelling.

0 · Reply

jetwash Jun. 26 at 6:38 AM

2 · Reply

theaussiebloke Jun. 26 at 1:12 AM

$ATHE Yesterdays presentation is now available on Alteritys presentations site...enjoy

1 · Reply

VicTruth17 Jun. 26 at 12:18 AM

1 · Reply

VicTruth17 Jun. 25 at 6:53 PM

2 · Reply

Denk333 Jun. 25 at 1:56 PM

$ATHE all in all solid call and good news came out of it. I can see a partnership or a buy out sometime in the next 2-3 months… hold and DCA

0 · Reply

theaussiebloke Jun. 25 at 1:12 PM

$ATHE In addition to other comments regarding this mornings presentation. Dr Stamler discussed other current treatments, which were antibody treatments through IV administration which had shown they dont penetrate the cell, yet ATH434, has shown and proven that it does, therefore treating the root cause...than also mentioned a pts statement that ATH434 should be in the hands of clinicians ASAP. There was alot to unpack, so I look forward to rewatching it, but absolutely nothing negative apart from a slight time extension.

1 · Reply

GA09 Jun. 25 at 11:21 AM

$ATHE I liked the call (ATHE). CEO did say they have been approached by multiple pharma companies (from very large to small) and he is (already) having constructive discussions as they have shown a keen interest in 434 and are (probably) waiting for data in July to pull (either) the partnership trigger or a buy-out. He did say they will partner with the right pharma who will give them a seat and a say in whole approval process and ensure the drug is (eventually) approved by the FDA. He also said a partnership would be good for the patients and the investors. He is also scheduling mini-sessions with the FDA and will be presenting data at multiple conferences this year. He also said he would prefer a partnership instead of a secondary resulting in dilution. Overall, the call was very constructive and they do have Orphan Drug Status, Fast Track Designation, a treatment not available for over 20+ years (unmet need), and a team with 3 FDA approvals. They get acquired within 6 months.

1 · Reply

tommy_john Jun. 25 at 12:56 AM

$ATHE $3-3.50 retest and then everyone forgets the call. lol

2 · Reply

tommy_john Jun. 25 at 12:55 AM

$ATHE it’s nice to be holding at a low cost. Meh. These things take time. What really changed except the timeline? Buyers will eat up cheap shares just watch

1 · Reply

Denk333 Jun. 25 at 12:17 AM

$ATHE what’s the news this one going south AH and it barely have volume

1 · Reply

VicTruth17 Jun. 25 at 12:03 AM

$ATHE mixed feelings…. I’ll list the Many catalyst I heard but the AA won’t be applied for until December…

1 · Reply

GA09 Jun. 24 at 11:44 PM

$ATHE Big Pharma is extremely interested!!!!! Big pharma to small pharma have shown a lot of interest. CEO just mentioned. At least 15 pharma companies are talking to them.

0 · Reply

GA09 Jun. 24 at 11:04 PM

$ATHE Listening to the call now.

0 · Reply

VicTruth17 Jun. 24 at 11:02 PM

$ATHE anyone else listening?

1 · Reply

VicTruth17 Jun. 23 at 5:34 PM

$ATHE What’s the board pumping in their minds? AA application? Partnerships for phase 3? Or self funded p3 in which we will get a nice haircut? No mention of the 202 advance stage? Pumped 💪🏽

1 · Reply

VicTruth17 Jun. 23 at 1:45 PM

$ATHE the feeling is materializing… let’s see what’s today best price :)

1 · Reply

Market Cap	36.80M
Revenue (ttm)	0.00
Net Income (ttm)	-12.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	14,956
Avg Vol	49,722
Day's Range	N/A - N/A
Shares Out	8.87M
Stochastic %K	42%
Beta	0.71
Analysts	Strong Sell
Price Target	$11.00